Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE JR versus OXTRIPHYLLINE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE JR versus OXTRIPHYLLINE PEDIATRIC.
AEROLATE JR vs OXTRIPHYLLINE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator